Wednesday, October 07, 2020 11:00:24 AM
NoveCite has a worldwide exclusive license from Novellus, an engineered cellular medicines company, to develop and commercialize NoveCite mesenchymal stem cells ("NC-iMSCs") to treat acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome ("ARDS") associated with COVID-19. Several cell therapy companies using donor-derived MSC therapies in treating ARDS have demonstrated that MSCs reduce inflammation, enhance clearance of pathogens and stimulate tissue repair in the lungs. Almost all these positive results are from early clinical trials or under the emergency authorization program.
NC-iMSCs are the next generation mesenchymal stem cell therapy. They are believed to be differentiated and superior to donor-derived MSCs. Human donor-derived MSCs are sourced from human bone marrow, adipose tissue, placenta, umbilical tissue, etc. and have significant challenges (e.g., variable donor and tissue sources, limited supply, low potency, inefficient and expensive manufacturing). iMSCs overcome these challenges because they:
Are more potent and secrete exponentially higher levels of immunomodulatory proteins;
Have practically unlimited supply for high doses and repeat doses;
Are from a single donor and clonal so they are economically produced at scale with consistent quality and potency, as well as being footprint free (compared to viral reprogramming methods); and,
Have significantly higher expansion capability.
Globally, there are 3 million cases of ARDS every year out of which approximately 200,000 cases are in the United States. The COVID-19 pandemic has added significantly to the number of ARDS cases. Once the COVID patients advance to ARDS, they are put on mechanical ventilators. Death rate among patients on ventilators can be as high as 50% depending on associated co-morbidities. There are no approved treatments for ARDS, and the current standard of care only attempts to provide symptomatic relief.
"NoveCite iMSCs have the potential to be a breakthrough in the field of cellular therapy for acute respiratory conditions because of the high potency seen in Novellus' pre-clinical studies, and because iMSCs are iPSC-derived, and therefore overcome the manufacturing challenges associated with donor derived cells," said Myron Holubiak, Chief Executive Officer of Citius.
"We are excited to be part of this effort because of the promise to save lives and reduce long term sequelae in patients with devastating respiratory diseases such as ARDS caused by COVID-19," said Dr. Matthew Angel, Chief Science Officer of Novellus. "Our iMSC technology has multimodal immunomodulatory mechanisms of action that make it potentially promising therapy to treat acute respiratory diseases."
Recent CTXR News
- Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences • PR Newswire (US) • 05/10/2024 12:30:00 PM
- Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering • PR Newswire (US) • 04/30/2024 08:05:00 PM
- Citius Pharmaceuticals Announces $15 Million Registered Direct Offering • PR Newswire (US) • 04/26/2024 12:00:00 PM
- Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma • PR Newswire (US) • 04/11/2024 12:30:00 PM
- Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference • PR Newswire (US) • 04/04/2024 12:30:00 PM
- Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma • PR Newswire (US) • 03/18/2024 12:30:00 PM
- Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program • PR Newswire (US) • 03/07/2024 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/04/2024 05:15:18 AM
- Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration • PR Newswire (US) • 02/26/2024 12:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/23/2024 09:23:46 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/23/2024 09:18:59 PM
- Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences • PR Newswire (US) • 02/23/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 01:45:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:40:26 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 02/14/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 02:18:38 PM
- Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma • PR Newswire (US) • 02/14/2024 01:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2024 09:08:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2024 09:05:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:05:27 PM
- Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors • PR Newswire (US) • 01/23/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:05:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:04:14 PM
- Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters • PR Newswire (US) • 01/02/2024 01:31:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM